TB-500

Widely used in veterinary medicine (racehorses). Human evidence is largely anecdotal. Preclinical wound-healing and cardiac-repair data are promising.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Extensive preclinical data on wound healing, cardiac repair, and neuroplasticity. Veterinary use is common. Human clinical trials are sparse but some are underway.

• Promotes cell migration and angiogenesis preclinically
• Cardiac repair effects in animal models
• Anti-inflammatory properties documented in vitro

Community protocols: 2–5 mg subcutaneously twice weekly during loading, then weekly. Not clinically validated.

• Injection-site reactions
• Headache
• Lethargy reported anecdotally

Not approved for human use. Gray-market products may contain partial sequences. Veterinary use does not validate human safety.

Strong preclinical rationale but near-zero published human trial data. Veterinary anecdotes are not substitutes for RCTs.

• Recovery45
• Pain30